Although antibody-drug conjugates (ADCs) are available for oncology care, the field of new and emerging novel ADCs is expanding rapidly. Many are in various stages of development for treatment of advanced solid tumors, and even though their general mechanisms are similar, the specific targets and rationales underlying each agent differ, making it challenging for oncology clinicians to remain up to date on development status, clinical trial data, and any new or potential approvals. This activity will highlight expert insights on new and emerging novel ADCs to enable clinicians to incorporate these agents into patient care in the clinical trial setting or once they are approved.
- Provider:Paradigm Medical Communications, LLC
- Activity Link: https://ce.paradigmmc.com/a/XCTSUR
- Start Date: 2024-05-31 05:00:00
- End Date: 2024-05-31 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.25 hours
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 48725.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 37500.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest